Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries an Avi tag (Avitag™) at the C-terminus.
The protein has a calculated MW of 39.8 kDa. The protein migrates as 50 kDa and 55 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>85% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Mouse IL-11 R alpha Protein, Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 85% (With Star Ribbon Pre-stained Protein Marker).
Immobilized Mouse IL-11 Protein, Fc Tag (Cat. No. IL1-M5243) at 5 μg/mL (100 μL/well) can bind Biotinylated Mouse IL-11 R alpha Protein, Avitag (Cat. No. ILR-M82E8) with a linear range of 0.1-5 ng/mL (QC tested).
Price(USD) : $350.00
Price(USD) : $1520.00
Price(USD) : $32.00
Price(USD) : $137.00
Price(USD) : $50.00
Price(USD) : $120.00
Price(USD) : $138.00
Price(USD) : $230.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Recombinant human interleukin-11 (Diao group) | Approved | Chengdu Diao Jiuhong Pharmaceutical Factory | 依星 | Mainland China | Thrombocytopenia | Chengdu Diao Jiuhong Pharmaceutical Factory | 2003-04-23 | Thrombocytopenia | Details | |
Recombinant human interleukin-11 (Shanghai CP Guojian) | Approved | Shanghai Cp Guojian Pharmaceutical Co Ltd | 欣美格 | Mainland China | Thrombocytopenia | Shanghai Cp Guojian Pharmaceutical Co Ltd | 2005-04-26 | Thrombocytopenia | Details | |
Recombinant human interleukin-11 for injection | Approved | Details | ||||||||
Recombinant human interleukin 11 (BioGeneric Pharma) | Approved | Biogeneic Pharma | Thrombocytopenia | Details | ||||||
Recombinant human interleukin-11 (Beijing ShuangLu Pharmaceutical) | Approved | Beijing Sl Pharmaceutical Co Ltd | 迈格尔 | Mainland China | Thrombocytopenia | Beijing Sl Pharmaceutical Co Ltd | 2003-03-17 | Thrombocytopenia | Details | |
Oprelvekin biosimilar (Hangzhou Jiuyuan Gene Engineering) | Approved | 吉巨芬, Jijufen | Mainland China | Thrombocytopenia | Hangzhou Jiuyuan Gene Engineering Co Ltd | 2003-09-18 | Thrombocytopenia | Details | ||
Recombinant human interleukin-11 (Qilu Pharmaceutical) | Approved | Qilu Pharmaceutical Co Ltd | 巨和粒 | Mainland China | Thrombocytopenia | Qilu Pharmaceutical Co Ltd | 2003-03-18 | Thrombocytopenia | Details | |
Recombinant human interleukin-11 (Kerun Biopharmaceutical) | Approved | Chongqing Kerun Biologic Pharmaceutical Development Co Ltd | 百杰依 | Mainland China | Thrombocytopenia | China Resources Angde Biotech Pharma Co Ltd | 2008-05-08 | Thrombocytopenia | Details | |
Recombinant human interleukin-11 (Xiamen Amoytop Biotech) | rHuIL-11 | Approved | Xiamen Amoytop Biotech Co Ltd | 特尔康 | Mainland China | Thrombocytopenia | Xiamen Amoytop Biotech Co Ltd | 2005-04-11 | Neoplasms; Thrombocytopenia | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Δ1-9, alanine 10, asparagine 134, recombinant human interleukin-11 | Phase 3 Clinical | Fuzhou Quanye Economic Technology Co Ltd | Thrombocytopenia | Details | |
NMX-1 | NMX-1 | Phase 2 Clinical | Novomedix LLC | Triple Negative Breast Neoplasms | Details |
LASN-01 | LASN-01 | Phase 1 Clinical | Csl Ltd | Pulmonary Fibrosis | Details |
This web search service is supported by Google Inc.